Stock-Based Compensation (Details) (USD $) | 0 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended |
Aug. 14, 2013 | Aug. 08, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Board of Directors | Board of Directors | Board of Directors | Board of Directors | Restricted Stock | Restricted Stock | Restricted Stock | Restricted Stock | Stock options | Stock options | Stock options | Stock options |
Common Stock Offering | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of shares which can be issued under the underwriting agreement relating to the public offering | ' | 3,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share price (in dollars per share) | ' | $11 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Term for which an over-allotment option was granted to the underwriters | ' | '30 days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of additional shares for which an over-allotment option was granted to the underwriters | ' | 495,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares price for which an over-allotment option was granted to the underwriters (in dollars per share) | ' | $11 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of shares of common stock issued | 3,795,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issue price per share of common stock (in dollars per share) | $11 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds from common stock sold, net of offering costs | $39,000,000 | ' | $39,021,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-Based Compensation | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation expense | ' | ' | ' | ' | ' | ' | ' | 989,000 | 591,000 | 2,500,000 | 1,600,000 | 14,000 | 60,000 | 134,000 | 181,000 |
Unrecognized stock-based compensation expense related to restricted stock | ' | ' | ' | ' | ' | ' | ' | 5,800,000 | ' | 5,800,000 | ' | ' | ' | ' | ' |
Non-vested stock activity, Number of Shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restricted stock that had not vested at the beginning of the period (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,247,668 | ' | ' | ' | ' | ' |
Granted (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | 299,500 | ' | ' | ' | ' | ' |
Cancelled (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | -190,561 | ' | ' | ' | ' | ' |
Shares vested (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | -145,250 | ' | ' | ' | ' | ' |
Restricted stock that had not vested at the end of the period (in shares) | ' | ' | ' | ' | ' | ' | ' | 1,211,357 | ' | 1,211,357 | ' | ' | ' | ' | ' |
Non-vested stock activity, Weighted Average Grant-Date Fair Value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restricted stock that had not vested at the beginning of the period (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | $7.47 | ' | ' | ' | ' | ' |
Granted (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | $11.21 | ' | ' | ' | ' | ' |
Cancelled (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | $8.75 | ' | ' | ' | ' | ' |
Shares vested (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | $8.34 | ' | ' | ' | ' | ' |
Restricted stock that had not vested at the end of the period (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $8.33 | ' | $8.33 | ' | ' | ' | ' | ' |
Unrecognized stock-based compensation expense related to stock options | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | 0 | ' |
Stock option activity, Number of Shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Outstanding options at the beginning of the period (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 568,040 | ' |
Options exercised (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -77,738 | ' |
Options cancelled (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,050 | ' |
Outstanding options at the end of the period (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 488,252 | ' | 488,252 | ' |
Exercisable options at the end of the period (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 488,252 | ' | 488,252 | ' |
Stock option activity, Weighted Average Exercise Price | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Outstanding options at the beginning of the period (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $3.49 | ' |
Options exercised (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $3.23 | ' |
Options cancelled (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $3.32 | ' |
Outstanding options at the end of the period (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $3.54 | ' | $3.54 | ' |
Exercisable options at the end of the period (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $3.54 | ' | $3.54 | ' |
Weighted Average Remaining Contract Life | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Outstanding options at the end of the period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years 6 months 25 days | ' |
Exercisable options at the end of the period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years 6 months 25 days | ' |
Other | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation expense | ' | ' | ' | $122,000 | $75,000 | $326,000 | $246,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of fully vested shares | ' | ' | ' | 9,000 | 9,000 | 27,000 | 27,000 | ' | ' | ' | ' | ' | ' | ' | ' |